explore -WSS

explore

author：leisure time 2025-09-01 15:18:43 - browse：5

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

WSS

Pregnancy ages women, but effects reverse after delivery

Dario to buy mental health app maker Twill in cash and stock deal

Community Health Systems hospitals under DOJ investigation

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

New documents shed light on MD Anderson Cancer Institute feud

Erich Jarvis studies song birds to learn about human stuttering

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

Adam's Take: Intra

Medicare proposal to cover medical devices draws a mixed reaction

What Kate Middleton's cancer revelation might teach the world

Medical records are filled with copy

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Activists slam private health insurers over coverage restrictions

What Kate Middleton's cancer revelation might teach the world

State Dept. review finds Biden bears some blame for Afghanistan failures

He's a Nobel laureate. Critics say he was misleading on Covid

entertainment

With Wegovy coverage, Medicare patients may face high costs

With competition flaring, obesity drug hits goal in liver disease study

With competition flaring, obesity drug hits goal in liver disease study

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Readout Newsletter: Illumina, CRISPR, Regeneron

Asbestos ban is immediate, but health effects will linger for decades

focus

knowledge

explore

focus